FDA clears Dexcom’s Stelo as first OTC glucose monitor for children

The FDA’s indication expansion for Dexcom’s Stelo makes it the first OTC CGM for paediatric patients, including those with diabetes. The FDA’s indication expansion for Dexcom’s Stelo makes it the first over the counter CGM available for children, including those with diabetes. The global CGM market is projected to reach a valuation of $15.69bn in 2035, as per GlobalData analysis. Credit: Around the World Photos / Shutterstock.com The US Food and Drug Administration (FDA) has cleared Dexcom’s Stelo glucose biosensor system for children, making it the first over-the-counter (OTC) continuous glucose monitor (CGM) for paediatric prediabetic and diabetic patients to…

Source: Medical Device Network